STANDARD BIOTOOLS INC. — Director's Dealing 2024

Jun 22, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2024-06-18

Reporting Person: Casdin Partners Master Fund, L.P. (Director, 10% Owner)
Reporting Person: Casdin Capital, LLC (Director, 10% Owner)
Reporting Person: Casdin Partners GP, LLC (Director, 10% Owner)
Reporting Person: Casdin Private Growth Equity Fund II, L.P. (Director)
Reporting Person: Casdin Private Growth Equity Fund II GP, LLC (Director)
Reporting Person: Casdin Partners FO1-MSV, LP (Director)
Reporting Person: Casdin Private Growth Equity Fund, L.P. (Director)
Reporting Person: CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (Director)
Reporting Person: Casdin Eli (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-18	Common Stock	J	655000	$2.05	Acquired	46730821	Indirect
2024-06-18	Common Stock	J	545000	$2.05	Acquired	545000	Indirect
2024-06-18	Common Stock	J	1200000	$2.05	Disposed	0	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13939637	Indirect
Common Stock	103556	Direct
Common Stock	2744219	Indirect
Common Stock	3774000	Indirect

Footnotes

F1: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 655,000 shares of Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund").

F2: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F3: Represents a cross-trade, pursuant to which Casdin FO1 transferred 545,000 shares of Common Stock to Casdin Amplify Fund, LP ("Amplify").

F4: The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F5: Represents a cross-trade, pursuant to which Casdin FO1 transferred 1,200,000 shares of Common Stock to the Master Fund and Amplify.

F6: The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F7: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.

F8: The securities are owned directly by Eli Casdin.

F9: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

F10: The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities.